StockData
Acadia Pharmaceuticals Inc logo

Acadia Pharmaceuticals Inc (ACAD) stock

ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3027% below fair value
$18.32−0.35 (-1.87%)

Close on Nov 17, 2026Market cap $3.16BP/E 8.3Yield –

Acadia Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Acadia Pharmaceuticals's pe ratio was 8.3× on Nov 11, 2026, against 16.2× a year earlier. Over the last 3 years it ranged from 3.9× to 92.1×, with a median of 11.6×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20268.3×−8.9
2025Dec 31, 202517.2×−6.3
2024Dec 31, 202423.5×+16.7
2012Jan 31, 20126.8×+1.9
2011Dec 30, 20114.9×–

More Acadia Pharmaceuticals figures

See a number that looks wrong?